Remicade and Humira


Remicade (infliximab) for Crohn’s disease has been approved for use in Manitoba under Pharmacare as of May 1, 2003. Humira (adalimumab) has been approved in Manitoba for use in Crohn’s disease since 2007. Physicians complete a request form and this is submitted to Manitoba Health. If approved, according to guidelines for use, Pharmacare will assign an “EDS” (Exceptional Drug Status) status to the prescription.
When a prescription comes into a pharmacy, the technicians check to see that it meets EDS. If the patient has met their Pharmacare deductible (issued annually to those who have applied for Pharmacare), then no further payment aside from the dispensing fee is required. If the patient has not met their deductible, then payment of the deductible would need to be made prior to receiving the medication.

To apply for Pharmacare, obtain a new Pharmacare application and Consent Authorization Form and send it to Manitoba Health along with copies of the Canada Customs and Revenue Agency Notice of Assessment, indicating the total income shown on line 150. You may apply for Pharmacare annually or a one-time enrollment. CCRA will notify Manitoba Health regarding your income automatically thereafter if the one-time enrollment form has been completed.

Pharmacare is based on both the total family income and the amount you pay for eligible prescription drugs. Not every drug is included in Pharmacare. Each year, patients are required to pay a portion (deductible) of the cost of their eligible prescription drugs. Some patients have private insurance and the insurance company will cover part or all of the cost of the drug (check with your insurance company first).

Janssen Canada has a financial support group (Remicare) to assist patients with their deductible or other cost related to Remicade (1-877-272-0784) based on income.

Abbott Canada has a financial support group (Progress) to assist patient with their deductible or other cost related to Humira 1-204-990-7112 based on income.

The Pharmacare web site is: